Page last updated: 2024-08-22
scandium and psma-617
scandium has been researched along with psma-617 in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Ahmadzadehfar, H; Bundschuh, RA; Eppard, E; Essler, M; Gaertner, FC; Khawar, A; Kürpig, S; Meisenheimer, M; Roesch, F; Sinnes, JP | 1 |
| Boros, E; Cingoranelli, SJ; Lapi, SE; Loveless, CS; Schlyer, D; Vaughn, BA | 1 |
Other Studies
2 other study(ies) available for scandium and psma-617
| Article | Year |
|---|---|
[44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma.
Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Male; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radioisotopes; Radiopharmaceuticals; Scandium; Tissue Distribution | 2018 |
Evaluation of
Topics: Animals; Chelating Agents; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Scandium; Tissue Distribution | 2021 |